Charissa Andreotti1, James C Root1, Sanne B Schagen2, Brenna C McDonald3, Andrew J Saykin3, Thomas M Atkinson1, Yuelin Li1, Tim A Ahles1. 1. Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 2. Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 3. Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract
BACKGROUND: The purpose of this study was to enhance the current understanding and interpretation of longitudinal change on tests of neurocognitive function in individuals with cancer. Scores on standard neuropsychological instruments may be impacted by practice effects and other random forms of error. METHODS: The current study assessed the test-retest reliability of several tests and overarching cognitive domains comprising a neurocognitive battery typical of those used for research and clinical evaluation using relevant time frames. Practice effect-adjusted reliable change confidence intervals for test-retest difference scores based on a sample of patient-matched healthy controls are provided. RESULTS: By applying reliable change confidence intervals to scores from two samples of breast cancer patients at post-treatment follow-up assessment, meaningful levels of detectable change in cognitive functioning in breast cancer survivors were ascertained and indicate that standardized neuropsychological instruments may be subject to limitations in detection of subtle cognitive dysfunction over clinically relevant intervals, especially in patient samples with average to above average range baseline functioning. CONCLUSIONS: These results are discussed in relation to reported prevalence of cognitive change in breast cancer patients along with recommendations for study designs that enhance detection of treatment effects.
RCT Entities:
BACKGROUND: The purpose of this study was to enhance the current understanding and interpretation of longitudinal change on tests of neurocognitive function in individuals with cancer. Scores on standard neuropsychological instruments may be impacted by practice effects and other random forms of error. METHODS: The current study assessed the test-retest reliability of several tests and overarching cognitive domains comprising a neurocognitive battery typical of those used for research and clinical evaluation using relevant time frames. Practice effect-adjusted reliable change confidence intervals for test-retest difference scores based on a sample of patient-matched healthy controls are provided. RESULTS: By applying reliable change confidence intervals to scores from two samples of breast cancerpatients at post-treatment follow-up assessment, meaningful levels of detectable change in cognitive functioning in breast cancer survivors were ascertained and indicate that standardized neuropsychological instruments may be subject to limitations in detection of subtle cognitive dysfunction over clinically relevant intervals, especially in patient samples with average to above average range baseline functioning. CONCLUSIONS: These results are discussed in relation to reported prevalence of cognitive change in breast cancerpatients along with recommendations for study designs that enhance detection of treatment effects.
Authors: Johna K Register-Mihalik; Kevin M Guskiewicz; Jason P Mihalik; Julianne D Schmidt; Zachary Y Kerr; Michael A McCrea Journal: J Head Trauma Rehabil Date: 2013 Jul-Aug Impact factor: 2.710
Authors: Wim Van der Elst; Martin P J Van Boxtel; Gerard J P Van Breukelen; Jelle Jolles Journal: J Int Neuropsychol Soc Date: 2006-01 Impact factor: 2.892
Authors: Otto Pedraza; Glenn E Smith; Robert J Ivnik; Floyd B Willis; Tanis J Ferman; Ronald C Petersen; Neill R Graff-Radford; John A Lucas Journal: J Int Neuropsychol Soc Date: 2007-05-18 Impact factor: 2.892
Authors: Tim A Ahles; Andrew J Saykin; Walter W Noll; Charlotte T Furstenberg; Stephen Guerin; Bernard Cole; Leila A Mott Journal: Psychooncology Date: 2003-09 Impact factor: 3.894
Authors: Tim A Ahles; Andrew J Saykin; Brenna C McDonald; Yuelin Li; Charlotte T Furstenberg; Brett S Hanscom; Tamsin J Mulrooney; Gary N Schwartz; Peter A Kaufman Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Debra E Lyon; Ronald Cohen; Huaihou Chen; Debra L Kelly; Angela Starkweather; Hyo-Chol Ahn; Colleen K Jackson-Cook Journal: J Cancer Res Clin Oncol Date: 2016-04-21 Impact factor: 4.553
Authors: Omar Saeed; Lori J Bernstein; Rouhi Fazelzad; Mary Samuels; Lynn A Burmeister; Lehana Thabane; Shereen Ezzat; David P Goldstein; Jennifer Jones; Anna M Sawka Journal: J Cancer Surviv Date: 2019-04-04 Impact factor: 4.442
Authors: Joseph M Gullett; Ronald A Cohen; Gee Su Yang; Victoria S Menzies; Robert A Fieo; Debra L Kelly; Angela R Starkweather; Colleen K Jackson-Cook; Debra E Lyon Journal: Psychooncology Date: 2019-03-14 Impact factor: 3.894
Authors: Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi Journal: J Pain Symptom Manage Date: 2020-01-15 Impact factor: 3.612